“Latest Statistics on Breast Cancer in India.” Breast Cancer India. https://www.breastcancerindia.net/statistics/latest_statistics_breast_cancer_india.html. Accessed Aug 2024.

“Breast Cancer.” World Health Organization. https://www.who.int/news-room/fact-sheets/detail/breast-cancer. Accessed Aug 2024.

Global health estimates: leading causes of death, 2000–2019. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death. Accessed Aug 2024.

Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. eClinicalMedicine. 2021;38:100985.

Article  PubMed  PubMed Central  Google Scholar 

Sopik V. International variation in breast cancer incidence and mortality in young women. Breast Cancer Res Treat. 2021;186:497–507.

Article  CAS  PubMed  Google Scholar 

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: global statistics for 2020 and 2040. The Breast. 2022;66:15–23.

Article  PubMed  PubMed Central  Google Scholar 

Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11(8):808. https://doi.org/10.3390/jpm11080808.

Article  PubMed  PubMed Central  Google Scholar 

Francies FZ, Hull R, Khanyile R, Dlamini Z. Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options. Am J Cancer Res. 2020;10:1568–91.

CAS  PubMed  PubMed Central  Google Scholar 

Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114: 108800. https://doi.org/10.1016/j.biopha.2019.108800.

Article  CAS  PubMed  Google Scholar 

Kim A, Mo K, Kwon H, Choe S, Park M, Kwak W, Yoon H. Epigenetic regulation in breast cancer: insights on epi-drugs. Epigenomes. 2023;7(1):6. https://doi.org/10.3390/epigenomes7010006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pramanik SD, Kumar Halder A, Mukherjee U, Kumar D, Dey YN. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Front Chem. 2022;10: 948217. https://doi.org/10.3389/fchem.2022.948217.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002. https://doi.org/10.1093/emboj/cdf616.

Article  PubMed  PubMed Central  Google Scholar 

Martínez-Balbás MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J. 2000;19(4):662–71. https://doi.org/10.1093/emboj/19.4.662.

Article  PubMed  PubMed Central  Google Scholar 

Yao YL, Yang WM, Seto E. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol. 2001;21(17):5979–91. https://doi.org/10.1128/MCB.21.17.5979-5991.2001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lopez JE, Haynes SE, Majmudar JD, Martin BR, Fierke CA. HDAC8 substrates identified by genetically encoded active site photocrosslinking. J Am Chem Soc. 2017;139(45):16222–7. https://doi.org/10.1021/jacs.7b07603.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Giorgio E, Brancolini C. Regulation of class IIa HDAC activities: it is not only matter of subcellular localization. Epigenomics. 2016;8(2):251–69. https://doi.org/10.2217/epi.15.106.

Article  CAS  PubMed  Google Scholar 

Zhang H, Shang YP, Chen HY, Li J. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res. 2017;47(2):149–59. https://doi.org/10.1111/hepr.12757.

Article  CAS  PubMed  Google Scholar 

Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016. https://doi.org/10.1101/cshperspect.a026831.

Article  PubMed  PubMed Central  Google Scholar 

Garmpis N, Damaskos C, Dimitroulis D, Kouraklis G, Garmpi A, Sarantis P, Koustas E, Patsouras A, Psilopatis I, Antoniou EA, Karamouzis MV. Clinical significance of the histone deacetylase 2 (HDAC-2) expression in human breast cancer. J Pers Med. 2022;12(10):1672. https://doi.org/10.3390/jpm12101672.

Article  PubMed  PubMed Central  Google Scholar 

Rahbari R, Rasmi Y, Khadem-Ansari MH, Abdi M. The role of histone deacetylase 3 in breast cancer. Med Oncol. 2022;39(7):84. https://doi.org/10.1007/s12032-022-01681-4.

Article  CAS  PubMed  Google Scholar 

Li A, Chen P, Leng Y, Kang J. Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3–COX2-dependent pathway. Oncogene. 2018;37(45):5952–66. https://doi.org/10.1038/s41388-018-0379-9.

Article  CAS  PubMed  Google Scholar 

Rahmani G, Sameri S, Abbasi N, Abdi M, Najafi R. The clinical significance of histone deacetylase-8 in human breast cancer. Pathol Res Pract. 2021;220: 153396. https://doi.org/10.1016/j.prp.2021.153396.

Article  CAS  PubMed  Google Scholar 

Huang Y, Jian W, Zhao J, Wang G. Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females. OncoTargets Ther. 2018. https://doi.org/10.2147/OTT.S164583.

Article  Google Scholar 

Zucchetti B, Shimada AK, Katz A, Curigliano G. The role of histone deacetylase inhibitors in metastatic breast cancer. The Breast. 2019;43:130–4. https://doi.org/10.1016/j.breast.2018.12.001.

Article  PubMed  Google Scholar 

Damaskos C, Valsami S, Kontos M, Spartalis E, Kalampokas T, Kalampokas E, Athanasiou A, Moris D, Daskalopoulou A, Davakis S, Tsourouflis G. Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res. 2017;37(1):35–46. https://doi.org/10.21873/anticanres.11286.

Article  CAS  PubMed  Google Scholar 

Ediriweera MK, Tennekoon KH, Samarakoon SR. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. Drug Discov Today. 2019;24(3):685–702. https://doi.org/10.1016/j.drudis.2019.02.003.

Article  CAS  PubMed  Google Scholar 

Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: promising agents for breast cancer treatment. Bioorg Chem. 2019;91: 103184. https://doi.org/10.1016/j.bioorg.2019.103184.

Article  CAS  PubMed  Google Scholar 

Lee RS, Sad K, Fawwal DV, Spangle JM. Emerging role of epigenetic modifiers in breast cancer pathogenesis and therapeutic response. Cancers. 2023;15(15):4005. https://doi.org/10.3390/cancers15154005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gregoretti I, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338(1):17–31. https://doi.org/10.1016/j.jmb.2004.02.006.

Article  CAS  PubMed  Google Scholar 

Karpac J, Jasper H. Metabolic homeostasis: HDACs take center stage. Cell. 2011;145(4):497–9. https://doi.org/10.1016/j.cell.2011.04.017.

Article  CAS  PubMed  Google Scholar 

Ma P, Pan H, Montgomery RL, Olson EN, Schultz RM. Compensatory functions of histone